9F81

Crystal structure of RIOK2 with a covalent compound GCL 47


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.02 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.214 
  • R-Value Observed: 0.217 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Probing the Protein Kinases' Cysteinome by Covalent Fragments.

Wang, G.Seidler, N.J.Rohm, S.Pan, Y.Liang, X.J.Haarer, L.Berger, B.T.Sivashanmugam, S.A.Wydra, V.R.Forster, M.Laufer, S.A.Chaikuad, A.Gehringer, M.Knapp, S.

(2024) Angew Chem Int Ed Engl : e202419736-e202419736

  • DOI: https://doi.org/10.1002/anie.202419736
  • Primary Citation of Related Structures:  
    8P7J, 8PM3, 9F32, 9F81, 9HHW

  • PubMed Abstract: 

    Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for highly related kinases is selectivity. Unlike their non-covalent counterparts, covalent inhibitors offer the advantage of selectively targeting structurally similar kinases by modifying specific protein side chains, particularly non-conserved cysteines. Previously, covalent fragment screens yielded potent and selective compounds for individual kinases such as ERK1/2 but have not been applied to the broader kinome. Furthermore, many of the accessible cysteine positions have not been addressed so far. Here, we outline a generalizable approach to sample ATP-site cysteines with fragment-like covalent inhibitors. We present the development of a kinase-focused fragment library and its systematic screening against a curated selection of 47 kinases, with 60 active site-proximal cysteines using LC/MS and differential scanning fluorimetry (DSF) assays, followed by hit validation through various complementary techniques. Our findings expand the repertoire of targetable cysteines within protein kinases, provide insight into unique binding modes identified from crystal structures and deliver isoform-specific hits with promising profiles as starting points for the development of highly potent and selective covalent inhibitors.


  • Organizational Affiliation

    Goethe-Universitat Frankfurt am Main Fachbereich 14 Biochemie Chemie und Pharmazie, Institute for Pharmaceutical Chemistry, GERMANY.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Serine/threonine-protein kinase RIO2A,
B [auth G]
330Homo sapiensMutation(s): 1 
Gene Names: RIOK2RIO2
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9BVS4 (Homo sapiens)
Explore Q9BVS4 
Go to UniProtKB:  Q9BVS4
PHAROS:  Q9BVS4
GTEx:  ENSG00000058729 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9BVS4
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.02 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.214 
  • R-Value Observed: 0.217 
  • Space Group: P 32
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 65.177α = 90
b = 65.177β = 90
c = 180.349γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
The Structural Genomics Consortium (SGC)Canada--

Revision History  (Full details and data files)

  • Version 1.0: 2025-01-08
    Type: Initial release